300 related articles for article (PubMed ID: 36472472)
1. Antibodies to watch in 2023.
Kaplon H; Crescioli S; Chenoweth A; Visweswaraiah J; Reichert JM
MAbs; 2023; 15(1):2153410. PubMed ID: 36472472
[TBL] [Abstract][Full Text] [Related]
2. Antibodies to watch in 2022.
Kaplon H; Chenoweth A; Crescioli S; Reichert JM
MAbs; 2022; 14(1):2014296. PubMed ID: 35030985
[TBL] [Abstract][Full Text] [Related]
3. Antibodies to watch in 2024.
Crescioli S; Kaplon H; Chenoweth A; Wang L; Visweswaraiah J; Reichert JM
MAbs; 2024; 16(1):2297450. PubMed ID: 38178784
[TBL] [Abstract][Full Text] [Related]
4. Antibodies to watch in 2021.
Kaplon H; Reichert JM
MAbs; 2021; 13(1):1860476. PubMed ID: 33459118
[TBL] [Abstract][Full Text] [Related]
5. Antibodies to watch in 2019.
Kaplon H; Reichert JM
MAbs; 2019; 11(2):219-238. PubMed ID: 30516432
[TBL] [Abstract][Full Text] [Related]
6. Antibodies to watch in 2018.
Kaplon H; Reichert JM
MAbs; 2018; 10(2):183-203. PubMed ID: 29300693
[TBL] [Abstract][Full Text] [Related]
7. Antibodies to watch in 2020.
Kaplon H; Muralidharan M; Schneider Z; Reichert JM
MAbs; 2020; 12(1):1703531. PubMed ID: 31847708
[TBL] [Abstract][Full Text] [Related]
8. A pivotal decade for bispecific antibodies?
Surowka M; Klein C
MAbs; 2024; 16(1):2321635. PubMed ID: 38465614
[TBL] [Abstract][Full Text] [Related]
9. Antibodies to watch in 2017.
Reichert JM
MAbs; 2017; 9(2):167-181. PubMed ID: 27960628
[TBL] [Abstract][Full Text] [Related]
10. Antibodies to watch in 2016.
Reichert JM
MAbs; 2016; 8(2):197-204. PubMed ID: 26651519
[TBL] [Abstract][Full Text] [Related]
11. Antibodies to watch in 2014: mid-year update.
Reichert JM
MAbs; 2014; 6(4):799-802. PubMed ID: 24846335
[TBL] [Abstract][Full Text] [Related]
12. Bispecific antibodies as monotherapy or in combinations for hematological malignancies: latest updates from the EHA 2023 annual meeting.
Li X; Zhang P; Sun H; Han L; Jiang Z; Yu J
Expert Opin Biol Ther; 2023; 23(12):1193-1195. PubMed ID: 37852928
[TBL] [Abstract][Full Text] [Related]
13. Antibodies to watch in 2015.
Reichert JM
MAbs; 2015; 7(1):1-8. PubMed ID: 25484055
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological profile of novel anti-cancer drugs approved by USFDA in 2022: A Review.
Sangwan K; Sharma V; Goyal PK
Curr Mol Med; 2023 Jun; ():. PubMed ID: 37350009
[TBL] [Abstract][Full Text] [Related]
15. Tixagevimab + Cilgavimab: First Approval.
Keam SJ
Drugs; 2022 Jun; 82(9):1001-1010. PubMed ID: 35727563
[TBL] [Abstract][Full Text] [Related]
16. Antibodies to watch in 2014.
Reichert JM
MAbs; 2014 Jan; 6(1):5-14. PubMed ID: 24284914
[TBL] [Abstract][Full Text] [Related]
17. Full-length recombinant antibodies from
Rashid MH
MAbs; 2022; 14(1):2111748. PubMed ID: 36018829
[TBL] [Abstract][Full Text] [Related]
18. Tixagevimab and Cilgavimab (Evusheld) boosts antibody levels to SARS-CoV-2 in patients with multiple sclerosis on b-cell depleters.
Conte WL; Golzarri-Arroyo L
Mult Scler Relat Disord; 2022 Jul; 63():103905. PubMed ID: 35661563
[TBL] [Abstract][Full Text] [Related]
19. Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients.
Nguyen Y; Flahault A; Chavarot N; Melenotte C; Cheminant M; Deschamps P; Carlier N; Lafont E; Thomas M; Flamarion E; Lebeaux D; Charlier C; Rachline A; Guérin C; Ratiney R; Touchard J; Péré H; Rozenberg F; Lanternier F; Arlet JB; Avouac J; Boussaud V; Guillemain R; Vignon M; Thervet E; Scemla A; Weiss L; Mouthon L;
Clin Microbiol Infect; 2022 Dec; 28(12):1654.e1-1654.e4. PubMed ID: 35926762
[TBL] [Abstract][Full Text] [Related]
20. Omalizumab: anti-IgE monoclonal antibody E25, E25, humanised anti-IgE MAb, IGE 025, monoclonal antibody E25, Olizumab, Xolair, rhuMAb-E25.
BioDrugs; 2002; 16(5):380-6. PubMed ID: 12408744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
